Healthia (ASX:HLA) - Managing Director & Group CEO, Wesley Coote
Managing Director & Group CEO, Wesley Coote
Source: Healthia
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Healthia (HLA) raises $44.5 million through a placement and the institutional component of its fully underwritten entitlement offer
  • The company recently flagged a $60 million capital raise to partially fund the acquisition of the Back in Motion Health Group and its 64 physiotherapy clinics
  • This purchase is set to position HLA as a leading provider of physiotherapy services in Australia and expand its presence to WA and New Zealand
  • Healthia will raise the remaining $15.5 million through the retail component of its entitlement offer which will be open from September 27 until October 6
  • Company shares are down 1.88 per cent to trade at $2.09

Healthia (HLA) has completed a placement and the institutional component of its fully underwritten one-for-4.3 pro rata non-renounceable entitlement offer.

As announced at the start of the week, Healthia is launching a $60 million capital raise to fund the acquisition of the Back in Motion Health Group and its 64 physiotherapy clinics throughout Australia and New Zealand for a cash and share consideration of $88.4 million.

Healthia considers the buy to be a strategic way of positioning it as a leading provider of physiotherapy services in Australia and expanding its presence to the WA and New Zealand markets.

The placement and institutional entitlement offer raised a combined total of about $44.5 million at a price of $1.80 per share.

The offer price represents an 18.2 per cent discount to the last closing price of $2.20 on September 17 and a 9.3 per cent discount to the five-day volume-weighted average price of $1.98.

Broken down, Healthia agreed to issue roughly 12.4 million shares to raise $22.3 million without the need for shareholder approval. The institutional offer raised $22.2 million through the issue of about 12.34 million shares and saw a significant take-up of entitlements by institutional shareholders.

The company expects to raise the remaining $15.5 million through the retail component of its entitlement offer which will be open from September 27 until October 6.

Company shares were down 1.88 per cent to trade at $2.09 at 1:50 pm AEST.

HLA by the numbers
More From The Market Online
The Market Online Video

Listen: From the Wire – Paradigm Biopharma CEO and Founder Paul Rennie

From The Wire: Senior markets reporter Jonathon Davidson sat down with Paradigm Biopharmaceuticals chief executive officer…
Lung imaging concept

Biotech lung imaging darling 4DX Medical back at $2.20/sh on Miami U contract

4DX Medical has seen its price jump back to $2.20/sh, as its next-gen lung imaging scan…
Chuffed bloke

Race Oncology’s placement-at-a-premium rewarded as shares jump +8%

Race Oncology has completed its recent A$3.2M placement – something that shareholders on the HotCopper forums…

Effective as an IV drug, a gel, and now an inhaler – Recce’s R327 can’t stop winning

Recce flagship antibacertial and anti-infective drug R327 has in a model that shows the drug could…